3 January 2023 -  Janssen today announced the submission of a marketing authorisation application to the EMA seeking approval of talquetamab for the treatment of patients with relapsed or refractory multiple myeloma. 

Talquetamab is an investigational, off the shelf (ready to use), bi-specific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal cells but over-expressed on myeloma cells, and CD3 on T-cells.

Read Janssen press release